A co-founder of the company ApconiX, based in Alderley Park, has revealed his view that attitude towards safety in pre-clinical cancer drug development needs to change.
Safety first
Dr Richard Knight will present his viewpoint in full during the forthcoming conference Accelerating Cancer Drug Development – from target to patients on 27 February.